This story has been deleted by the news provider.
DELETED: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
On 6ix: 6ix.com/news/deleted-protagenic-therapeutics-announces-receipt-nasdaq-non-compliance-notice-2025
Protagonist Therapeutics, Inc. on 6ix
Earlier from Protagonist Therapeutics
- Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
- Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
- Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
- Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Later from Protagonist Therapeutics
- Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera
- Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
- Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
- Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
- Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Follow Protagonist Therapeutics into a list and get an email when it puts out news.
Follow Protagonist Therapeutics